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Introduction
Plasma exchange (PE) is the most commonly performed ther-
apeutic apheresis procedure, according to data from interna-
tional registries [1]. The basic premise of PE is that the removal 
of pathological or pathologically elevated substances will reduce 
further damage and may permit reversal of the pathologic pro-
cess [2]. PE is recommended in several indications [3]. Primary 
hypothyrodism, mainly Hashimoto’s autoimmune thyroiditis, is 
a frequent disorder with a prevalence of 0.3% for clinical and 
4.3% for subclinical hypothyroidism [4]. Thyroxin (T4) is mainly 
bound to thyroxin binding protein (TBG), albumin, and to a 
smaller extent to transthyretin. PE removes these binding pro-
teins resulting in major changes of the total hormone pool (TT4). 
In contrast to most other hormones, like insulin, cortisol and sex 
hormones that are rapidly cleared from the circulation and re-
secreted again if needed, T4 has an especially prolonged half-life 
time of around 7 days, a small fraction of free hormone (free thy-
roxine (fT4) around 0.03%) and a quite stable plasma level 
throughout the day. In addition to the shift from bound to freely 
available thyroid hormone, the pituitary-thyroid axis is thought 
to compensate for a PE-induced reduction in TT4 in a physiolog-
ical condition [5]. However, pharmacodynamic studies or data 
about an adaptation of a given thyroid replacement therapy in 
view of a PE in a patient with hypothyroidism are currently not 
available.
We, therefore, aimed at investigating the effect of PE on thyroid 
hormone metabolism in a patient with therapy-resistant polyneu-
ropathy who was treated for primary hypothyroidism (Hashimo-
to’s thyroiditis). 
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Summary
Background: Pharmacodynamic studies and data con-
cerning adaptation of thyroid substitution in patients 
with substituted hypothyroidism during plasma ex-
change (PE) is not available. Case Report: We measured 
TSH, fT3 and fT4, total T4, thyroxin binding globulin 
(TBG), and albumin before and after 5 PE procedures in a 
37-year-old women who underwent PE for a therapy-re-
sistant polyneuropathy. Thyroxin was increased empiri-
cally by 8% resulting in a dose of 1.95 μg/kg per day. Re-
sults: Despite larger reductions of total T4 and TBG over 
a series of 5 PEs (40–50% from baseline), only small re-
ductions of 8% in fT3 and fT4 concentrations were docu-
mented with a concomittant increase in TSH level. 
Changes of fT4, fT3, and TSH remained within normal 
range. Conclusions: i) Despite a significant decrease in 
total thyroid hormone pool following PE, fT4, fT3, and 
TSH concentrations changed only slightly. ii) Based on 
this observation, a general increase in thyroid replace-
ment therapy before PE cannot be recommended, but 
considered in case of a high normal TSH level.
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Case Report
An informed consent form was signed by the patient approving the use of 
material or information for scientific purposes. 
We present the case of a 37-year-old woman with a severe painful periph-
eral polyneuropathy for 3 years. The etiology could not be determined although 
a chronic inflammatory demyelinizing polyneuropathy was suspected. An ini-
tial treatment with oral steroids did not relieve symptoms. Also a therapy with 
intravenous immunoglobulins did not result in satisfactory symptomatic relief. 
Due to persistent symptoms a series of PEs was planned. The patient was 
known for primary hypothyroidism due to Hashimoto’s thyroiditis since the 
age of 10 with documented elevated TPO antibodies. She was on stable thyroid 
replacement therapy.
Methods
PE Procedures 
The mobile centrifugal apheresis system Spectra Optia (TerumoBCT, Lake-
wood, CO, USA) was used. Procedures were conducted by qualified nurses su-
pervised by a trained physician. Within 14 days a total of 5 PEs were performed 
every 2–5 days. Each time the 1.2-fold of the patient’s own plasma volume was 
replaced using a 5% albumin solution (CSL Behring AG, Bern, Switzerland) 
containing at least 96% albumin according to the manufacturer and physiologic 
saline (Sintetica SA, Couvet, Switzerland) in a ratio of 2: 1. 
We used citrate (ACD-A, Bichsel SA, Interlaken, Switzerland) as antico-
agulant, following the manufacturers’ instructions. Routinely, an intravenous 
continuous infusion of calcium chloride (Calcium-Sandoz 10%, Sandoz AG, 
Risch, Switzerland) throughout the PE was performed. The initial infusion rate 
corresponded to the administration of median 0.25 mg of ionized calcium 
(Ca2+) per milliliter of ACD-A (0.53 mmol Ca2+ / 10 mmol citrate) [6].
Substitution
The patient presented with a thyroid-stimulating hormone (TSH) level 
of 3.36 mU/l at baseline under a stable levothyroxine dose of 129 μg/day 
(1.81 μg/kg/day). As we anticipated a loss during PE, we empirically increased 
the substitution dose to 139 μg/day (+8%; 1.95 μg/kg/day) 3 weeks before the 
first PE. After the last PE the patient returned to her usual dose. 
Laboratory Samples
Plasma samples were drawn before and immediately after PE. TSH, fT3 (free 
liothyronine), and fT4 were determined using electro-chemiluminescence 
 immunoassay (Modular E170; F. Hoffmann-La Roche AG, Basel, Switzerland), 
and for albumin the bromcresol purple method was used (Modular P800; F. 
Hoffmann-La Roche AG) using routine laboratory. TT4 and TBG was deter-
mined using the Chemiluminescent Microparticle Immunoassay, Architect 
(Abbott  Laboratories, Abbott Park, IL, USA) and a radio immunoassay, respec-
tively, in an external laboratory (Laboratoire chimie clinique, Endocrinologie, 
Centre hospitalier universitaire Vaudois, Lausanne). 
Statistical Analysis 
Due to the small sample size only descriptive methods (arithmetic mean) for 
changes are reported. We calculated immediate differences (value post-PE 
minus value pre-PE) of all 5 procedures (both in absolute and relative terms, the 
mean ± SD of 5 plasmaphereses is given). The relative immediate differences 
reflect real removal and were calculated as: 100 – ((value post-PE × 100) / value 
pre-PE). Assuming a one-compartment model, a predicted removal can be 
 calculated as: 100 – (((value pre-PE × e–x) × 100) / value pre-PE), where x is the 
plasma exchanged [7].
A new steady-state condition was assumed to be reflected by the values 
measured before each PE. We, therefore, calculated differences from the begin-
ning of one PE to the next. The mean (± SD) of 4 steady-state differences in 
 absolute and relative terms is reported. In order to determine whether or not 
the number of PE impacts on the different parameters of thyroid hormone 
 metabolism the values before the first and the last procedure were considered. 
Results 
Clinical Course 
Clinically, a focused history did not reveal any symptoms of a 
dysthyroid condition throughout the procedures. In electroneu-
rography studies, minor improvements of polyneuropathy param-
eters could be detected. However, the patient reported no subjec-
tive improvement after the 5 PEs. The treatment was, therefore, 
discontinued after 5 procedures.
Laboratory Values 
The minor dose increase of thyroid replacement therapy 3 weeks 
before the first PE resulted in a reduction of TSH levels slightly below 
the lowest limit of normal range (0.22 mU/l; normal range 0.27–4.5 
mU/l). The changes of the thyroid function tests and the related 
binding proteins are shown in figure 1. Before the first and the last 
PE the TSH increased from 0.22 to 1.87 mU/l, fT4 decreased from 
19.7 to 16.7 pmol/l and fT3 from 4.78 to 3.45 pmol/l (all within nor-
mal range). TT4 was 95 nmol/l before the 1st and 77 nmol/l before 
the 5th PE (normal range 60–150 nmol/l). TBG completely recovered 
after each PE. Albumin remained constant, as it was substituted. 
Immediate changes* (n = 5) Steady-state changes** (n =4 )
absolute relative absolute relative 
TSH, mU/l –0.37 ± 0.30 –45.9 ± 6.3% 0.41 ± 0.48 37.8 ± 25.0%
fT4, pmol/l –1.4 ± 1.0 –7.9 ± 5.7% –0.75 ± 1.6 –4.5 ± 9.0%
TT4, nmol/l –36 ± 8.3 –45.4 ± 6.6% –4.5 ± 10.5 –6.1 ± 14.4%
fT4/TT4, % 0.0183 ± 0.0082 80.3 ± 34.4% 0.00025 ± 0.0024 0.76 ± 10.1%
fT3, pmol/l –0.29 ± 0.12 –6.9 ± 2.1% –0.33 ± 0.08 –8.5 ± 2.1%
TBG, mg/l –11.0 ± 2.35 –62.0 ± 7.4% –0.25 ± 4.35 –4.0 ± 28.4%
Albumin, g/l –0.2 ± 3.1 –0.3 ± 8.2% 0.75 ± 1.5 1.9 ± 3.8%
*Immediate changes were calculated from pre to post plasma exchange. 
**Steady-state values were calculated from pre plasma exchange up to the next pre plasma exchange (i.e. 
from full circle to full circle in fig. 1)
Table 1. Immediate and steady-state changes  
of thyroid function tests and related binding 
 proteins during 5 courses of PE and their related 
changes
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Thyroid Hormone Substitution during Plasma 
Exchange
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In table  1 the PE-induced immediate changes are compared 
with steady-state changes. Assuming a one-compartment model, a 
removal of 69.9% would be expected. Total T4 fell on average by 45 
± 6.3% during each PE, reflecting the reduction of TBG by 62 ± 
7.4%. The relative decrease in TSH concentrations was similar 
(45.9 ± 6.3%). The free hormones were only reduced by 7.9 ± 5.7% 
for fT4, and by –6.9 ± 2.1% for fT3. Consequently, the ratio of fT4 
to TT4 increased significantly. 
In the steady state the TBG changes were largely abolished (–6.1 
± 14.4%), as were TT4 changes (–4.5 ± 9.0%), but for TSH an in-
crease was found (37.8 ± 25.0%). The reductions in free hormone 
concentrations were comparable to the immediate changes (–4.5 ± 
9.0% for fT4, –8.5 ± 2.1% for fT3). The free-to-bound ratio re-
mained constant over the course of the PE.
Discussion
The main results from this report are three-fold: i) A PE induces 
an immediate decrease in TT4 and TBG below normal range that 
recovers and stabilizes in the lower half of normal range after 5 
consecutive procedures. ii) Five PE within 14 days resulted in a 
steady decrease in fT4 and fT3 concentrations and an increase in 
TSH levels, albeit all within normal range. iii) Based on these find-
ings, an increase in the dose of thyroid replacement therapy before 
PE cannot be generally recommended. A thyroid replacement dose 
inducing a TSH in the lower normal range can be considered be-
fore starting the first PE. 
Acute changes of thyroid parameters included a decrease in TT4 
pool in parallel with a decrease in TBG. Interestingly, the values 
Fig. 1. Thyroid function tests and related binding 
proteins across 5 PEs in a patient with substituted 
primary hypothyroidism. Dashed lines indicate 
normal reference values. Full circles indicate values 
before and hollow circles values post plasma 
 exchange. 
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immediately after the PE were lower than the normal range. This is 
not surprising since 99.97% of T4 is bound, with about three quar-
ters bound to TBG. In fact, TT4 relates to the 3,400-fold of the free 
hormone pool. The removal of TBG (–62%) was close to the ex-
pected value (–69.9%), whereas TT4 was somewhat lower (–45%). 
The lower than expected values could be due to TBG and T4 in-
cluded in the albumin preparation, a similar effect has been shown 
for haptoglobin [7]. In contrast, fT4, and fT3 decreased only slightly 
– far off from a logarithmical removal – indicating a shift from the 
bound T4 pool to the free T4 fraction. This is reflected by an in-
crease in the fT4/TT4 ratio and may explain the lack of significant 
clinical symptoms and signs throughout the procedures. There is a 
tendency for an increase in TT4 during the last PE, while TBG re-
mained stable throughout the procedures. Apart from a possible 
increase in production rate of TBG, possibly there was also a re-
verse flow of extravascular T4 as shown in a rabbit model [8].
PE has been described as an effective method of last therapeutic 
resort for therapy-resistant thyrotoxicosis [9] and thyroxine intoxi-
cation [10]. In both situations substantially higher fT4 levels are 
reported based on an enhanced endogenous production or intake. 
Due to the ongoing endogenous production, PE is rather consid-
ered a temporal relief therapy before definitive surgery. Taking in 
account the current observation of only small reductions in fT4 and 
fT3 and only insignificant reductions of fT4 in one retrospective 
study [9] following PE, the utility of such a procedure has to be 
questioned, although it may be a life-saving procedure for thyroid 
storm in the case of intoxication [11]. 
There is a steady decrease in fT4 and fT3 with a concomitant in-
crease in TSH after 5 procedures, albeit within normal range. This 
indicates that – in contrast to TT4 and TGB – the compensatory 
mechanisms are not capable to guarantee completely stable fT4 and 
fT3 levels throughout several PEs, and more than 5 PEs may even-
tually result in a hypothyroid condition. Compensatory mecha-
nisms include the shift from bound to free thyroid hormone pool 
and/or TSH-stimulated production of thyroid hormone. The cur-
rent study was not designed to differentiate between these mecha-
nisms. However, the observation of an increase in the fT4/TT4 ratio 
and TSH levels suggest that both mechanisms were probably in-
volved. Interestingly, in euthyroid patients without Hashimoto’s 
thyroiditis, PE was reported not to result in significant changes of 
free hormones despite the fact that similar changes for TT4 and 
TBG were observed [5]. 
Limitations
The main limitation of this report is that it is restricted to one 
subject with only 5 instances of PE. Clinically more relevant 
changes may become apparent in patients with more than 5 
procedures.
Strength 
The setting has been highly standardized with a sufficient tem-
poral resolution and additional measurement of clinically now 
rarely used parameters. 
Recommendation
Based on these data it appears reasonable to aim for a TSH level 
in the lower normal range before plasma exchange is initiated. At 
least for 5 consecutive PEs, a general increase in thyroid substitu-
tion dose cannot be recommended. However, if more than 5 proce-
dures are planned in a series, an adaption of thyroid hormone re-
placement dose may be considered. After plasma exchange the 
original substitution regimen can be re-adopted. Frequent meas-
urements of TSH, fT3, and fT4 are mandatory to further adapt the 
substitution dose.
Conclusion 
Despite a significant decrease in TT4 following plasma ex-
change, fT4, fT3 and TSH concentrations changed only slightly. 
Based on this observation, a general increase in thyroid replace-
ment therapy before plasma exchange cannot be recommended. 
An increase in substitution dose can be considered in case of a 
high normal TSH level. 
Plasma exchange in patients with substituted hypothyroidism 
may serve as a system’s pertubation tool to investigate the physiol-
ogy of thyroid hormones and their binding proteins. Results from 
such observations may help quantify expected losses for future 
patients. 
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